RajivAgarwal United States

Upload Picture

First name

Rajiv

Last name

Agarwal

Institution

Country

United States

Time	Session

2:15 p.m. 3:45 p.m.	HIT! High Impact Clinical Trials – What and Why HIT1 Andrea Vichelli Chair andrea.viecelli@health.qld.gov.auAustraliaUniversity of Queensland VivekKumar Chair enigma165@yahoo.co.inIndiaPostgraduate Institute of Medical Education and Research, Chandigarh, India Combination Effect of Finerenone and Empagliflozin in Participants With Chronic Kidney Disease and Type 2 Diabetes Using a UACR Endpoint Study (CONFIDENCE) HIT1-1 RajivAgarwal Oral Abstract Presenter ragarwal@iu.eduUnited States Results From the REGENCY Trial Assessing Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis HIT1-2 BradRovin Oral Abstract Presenter rovin.1@osu.eduUnited StatesThe Ohio State University Clinical and Safety Outcomes of Semaglutide by CKD Severity in the FLOW trial HIT1-3 KatherineTuttle Oral Abstract Presenter Katherine.Tuttle@providence.orgUnited StatesUniversity of Washington School of Medicine, Division of Nephrology Brahmkamal Hall - Plenary Hall

Time

Session

2:15 p.m.

3:45 p.m.

HIT! High Impact Clinical Trials – What and Why

Andrea Vichelli Chair andrea.viecelli@health.qld.gov.auAustraliaUniversity of Queensland

VivekKumar Chair enigma165@yahoo.co.inIndiaPostgraduate Institute of Medical Education and Research, Chandigarh, India

Brahmkamal Hall - Plenary Hall